Following a strong 2024, this year has started on a positive note for cell- and gene company Elicera Therapeutics. In January, the company announced that the first patient treated in a study of the CAR T-cell therapy ELC-301 is now tumour-free. Elicera is now focusing on strengthening its financial position through the ongoing subscription period of TO2. BioStock reached out to CEO Jamal El-Mosleh to learn more.
- We have several important and potentially value-driving milestones to present throughout the year from both of our clinical programs, says El-Mosleh.